China Unveils Sweeping Reform of Pediatric Drug System

On April 22, 2026, China’s National Health Commission (NHC), together with seven other central government agencies including the National Medical Products Administration (NMPA), issued the “Implementation Opinions on Reforming and Improving the Supply Guarantee Mechanism for Children’s Medicines.” The eight-agency joint issuance is itself a signal: this is a whole-of-government commitment, not a single-regulator initiative.

Publicly released on May 7, the framework marks China’s most significant pediatric medicine policy overhaul in more than a decade.

More importantly, the reforms reflect a shift in regulatory thinking. Historically, pediatric medicine policy in China focused primarily on addressing shortages and improving access to child-appropriate medicines. The new framework retains those objectives but expands considerably beyond supply considerations, introducing a coordinated lifecycle approach spanning innovation, clinical evidence generation, manufacturing, reimbursement, procurement, hospital use, pharmaceutical services, and public medication management.

For pharmaceutical companies, pediatric medicines are no longer being treated solely as a niche public-health category. The reforms position pediatric development as an increasingly integrated component of China’s broader pharmaceutical innovation strategy.

At a Glance: China’s Pediatric Medicine Reform Framework

• Major policy reset: China replaces its 2014 pediatric drug framework with a unified system covering the full medicine lifecycle from R&D to clinical use
• Stronger R&D incentives: Priority review, rolling submissions, NRDL pathways, and potential exclusivity support faster development and approval
• Expanded clinical evidence base: New national trial networks and greater use of real-world evidence and data extrapolation to support pediatric indications
• Supply and manufacturing tightening: Stronger controls on production capacity, quality oversight, traceability, and shortage prevention systems
• Broader system integration: Reforms extend into hospital prescribing, procurement, labeling standards, and public medication management

New Policy Replaces China’s 2014 Pediatric Medicine Framework

The reforms formally replace China’s 2014 pediatric medicine framework, which regulators determined no longer addressed persistent structural weaknesses in the market, including:

• Shortages of child-appropriate formulations
• Incomplete pediatric labeling information
• Weak incentives for low-demand but clinically necessary medicines
• Uneven pharmaceutical service capacity across healthcare institutions

Rather than narrowly targeting drug supply, the new framework introduces a system-wide reform agenda spanning:

• Drug research and development
• Clinical evidence generation
• Manufacturing and supply security
• Reimbursement and procurement
• Hospital use and pharmaceutical services
• Public health education and medication management

The result is a far more integrated approach to pediatric medicine governance and higher expectations for clinical evidence, lifecycle management, and compliance.

Expanded Support for Pediatric Drug R&D

A major focus of the reforms is strengthening pediatric drug innovation and accelerating development of medicines specifically designed or evaluated for pediatric use.

According to the policy, China’s major national science and technology programs will now support:

• Innovative therapies for common pediatric diseases
• Combination vaccines
• Pediatric formulations with approved indications and dosage instructions

Priority Review and Development Incentives

China will also continue improving support policies linked to the “List of Encouraged Pediatric Drug Development Applications” and the “Catalogue of Encouraged Generic Drugs.”

Medicines included in these lists may receive:

• Priority review and approval
• Priority consideration for inclusion in the National Essential Medicines List
• Eligibility for inclusion in national innovation programs
• Potential inclusion in the National Reimbursement Drug List (NRDL) 

Early Regulatory Intervention and Rolling Submissions 

The framework also introduces greater regulatory flexibility for designated innovative pediatric medicines. Regulators may: 

• Intervene earlier during development
• Coordinate review and inspection activities simultaneously
• Permit rolling submission of application materials 

The policy does not specifically address foreign applicants by name, but these mechanisms apply to all designated innovative pediatric medicines regardless of origin. Foreign companies pursuing pediatric registrations in China should factor rolling submissions and concurrent review-inspection into their development timelines. 

China Expands Pediatric Clinical Research Infrastructure 

The framework also aims to strengthen China’s pediatric clinical research ecosystem and evidence-generation capacity. 

China plans to support the establishment of pediatric research wards at National Medical Centers, National Regional Medical Centers, and National Clinical Medical Research Centers, alongside a national pediatric clinical trial collaboration network and cross-institutional ethics review mechanisms. 

The reforms further encourage:

• Multicenter pediatric research collaboration
• Unified data standards and analytical norms
• Greater use of real-world evidence
• Prospective study designs
• Collaborative research on medicines widely used in children but lacking pediatric labeling information

Greater Use of Real-World Evidence and Data Extrapolation 

Importantly, the policy states that existing adult safety data from Chinese populations may be extrapolated to Chinese pediatric populations where scientifically appropriate. 

For companies pursuing pediatric indication expansion in China, this is a directly usable pathway. Where regulators consider extrapolation scientifically justified, existing adult safety data from Chinese populations can support labeling updates without requiring a full independent pediatric trial program. 

Pediatric Labeling Modernization 

The reforms also target long-standing gaps in pediatric package insert information. 

Qualified healthcare institutions and industry associations are encouraged to propose updates to pediatric indications, dosage instructions, and safety information for marketed chemical drugs and therapeutic biologics. 

Authorities also emphasized the need to standardize pediatric package insert information, including updated dosage instructions and safety information. 

Greater Oversight of Evidence-Based Off-Label Pediatric Use 

The policy further recognizes that evidence-based pediatric use may occur under legally permitted circumstances even where approved pediatric labeling is unavailable. 

Healthcare institutions adopting such practices will be expected to: 

• Conduct medication assessments 
• Establish internal management systems 
• Review prescription appropriateness 
• Strengthen oversight of prescribing behavior 

The policy also calls for authoritative institutions to develop standards supporting evidence-based pediatric off-label use in alignment with regulatory requirements. 

Dedicated Support for Pediatric Traditional Chinese Medicine 

Alongside reforms targeting conventional pharmaceuticals, the framework establishes a dedicated policy track for pediatric traditional Chinese medicine (TCM). 

According to the policy, China will support development of: 

• Pediatric Chinese patent medicines
• Pediatric hospital TCM preparations
• Improved formulations designed to enhance adherence

The reforms also call for pediatric-specific TCM research models and evidence systems, while regulators establish a list of pediatric conditions with recognized TCM advantages to accelerate evidence collection and commercialization. 

Package insert requirements for pediatric Chinese patent medicines will also be strengthened, including pediatric indications, dosage instructions, and safety warning information.

New Measures Target Manufacturing and Supply Resilience

Another major objective of the reforms is strengthening pediatric medicine manufacturing capacity and reducing shortages.

China will continue implementing pharmaceutical industry initiatives aimed at improving pediatric medicine supply, including support for pediatric formulations and specifications.

Designated manufacturers of low-volume and shortage medicines will also be encouraged to expand pediatric production capacity.

Shortage Prevention and Supply Monitoring

Authorities also plan to strengthen production monitoring and supply guarantees for key pharmaceutical inputs, including excipients, while expanding central and local reserves of pediatric medicines.

During seasonal outbreaks, regulators will enhance:

• Supply monitoring
• Information sharing
• Early-warning systems

These measures are intended to stabilize supplies of commonly used pediatric medicines such as antivirals and antipyretics.

Expanded Traceability and Quality Supervision

The framework also expands quality supervision requirements across pediatric medicine supply chains.

Regulators will gradually establish one-item-one-code traceability systems while increasing inspections and sampling activities for pediatric medicines and pediatric hospital preparations.

Additional measures include:

• Enhanced adverse reaction monitoring
• Greater scrutiny of products sold significantly below cost
• Closer oversight of frequent manufacturing process or excipient changes
• Support for manufacturing upgrades and digital transformation initiatives

For manufacturers supplying the Chinese market, supply continuity, traceability, pharmacovigilance, and manufacturing oversight are becoming increasingly integrated regulatory expectations rather than standalone compliance activities.

Expanded Reimbursement and Intellectual Property Incentives

Expanded NRDL and Insurance Support

Eligible products may qualify for inclusion in China’s National Reimbursement Drug List, including:

• Medicines listed in the encouraged pediatric development catalog
• Pediatric-only medicines
• Pediatric formulations
• Medicines with clear pediatric dosage instructions

The framework also states that negotiated medicines adding pediatric indications during reimbursement agreement periods may qualify for simplified renewal procedures.

Commercial health insurers are additionally encouraged to develop pediatric insurance products covering innovative and rare disease medicines.

Eligible Products May Receive Up to Two Years of Market Exclusivity

The policy also introduces additional intellectual property protections for eligible pediatric medicines.

Innovative pediatric medicines, new pediatric formulations or specifications, and medicines with newly added pediatric indications may receive up to two years of market exclusivity where eligible.

Authorities further confirmed that eligible pediatric medicine patents may qualify for patent term extensions under China’s pharmaceutical intellectual property framework. Clinical trial data and other eligible submitted materials will receive legal protection where applicable.

Taken together, these measures may strengthen commercial incentives for companies developing pediatric therapies and pediatric formulations for the Chinese market.

Procurement and Hospital Supply Systems Face Major Changes

The policy also introduces provisions on procurement pathways, pediatric hospital preparations, healthcare service responsibilities, and medication education initiatives, with key details outlined below.

Separate Procurement Pathways for Pediatric Medicines

Under the policy, pediatric-only medicines will be grouped separately from adult medicines during national centralized volume-based procurement processes.

Provincial procurement platforms are expected to implement provincial listing rules and optimize price-difference mechanisms to encourage the supply of pediatric formulations and specifications.

Expanded Role for Pediatric Hospital Preparations

Authorities also stated that hospital pediatric preparations should play a greater role in addressing shortages and unmet clinical needs.

The lawful transfer and use of these preparations within medical consortium institutions will be supported to help accumulate pediatric clinical experience.

China additionally plans to establish a national list of commonly used pediatric hospital preparations for clinically necessary products unavailable commercially or lacking appropriate pediatric formulations or specifications.

Expanded Hospital and Pharmaceutical Service Responsibilities

Secondary and higher-level medical institutions providing pediatric services must regularly evaluate and adjust pediatric medicines within their formularies, while pediatric medicines may be exempt from China’s “one product, two specifications” restriction during formulary selection.

The framework also encourages healthcare institutions to expand pediatric pharmaceutical services, prescription review systems, multidisciplinary medication management programs, and pharmacist-led education initiatives.

In parallel, regulators plan to strengthen rational medication use oversight through expanded prescription review systems, pharmacist verification procedures, and prescription evaluation mechanisms.

Public Education and Medication Management

Healthcare institutions will be expected to strengthen guidance for guardians on proper medication use and establish follow-up systems supporting pediatric medication management.

Medical institutions are also encouraged to use digital platforms and community outreach programs to promote:

• Rational medication use
• Preventive healthcare education
• Scientific parenting practices
• Improved medication adherence

Authorities additionally plan broader public education campaigns focused on safe pediatric medication practices.

Final Thoughts: China’s Pediatric Policy Enters a New Integrated Phase

China’s 2026 pediatric medicine reforms represent a significant evolution from the narrower supply-focused policies introduced in 2014. While improving access remains a central objective, the new framework extends well beyond supply management and introduces a more integrated approach covering innovation, evidence generation, manufacturing, reimbursement, procurement, hospital use, and pharmaceutical care.

For pharmaceutical companies, the direction is clear. China is expanding support for pediatric innovation while simultaneously raising expectations around clinical evidence, labeling quality, supply resilience, traceability, and lifecycle compliance.

Several aspects of the framework are particularly noteworthy. Expanded use of real-world evidence and data extrapolation may create new opportunities for pediatric indication development. The combination of priority review, rolling submissions, reimbursement support, intellectual property incentives, and potential market exclusivity strengthens the commercial case for pediatric development programs. At the same time, enhanced quality oversight, traceability requirements, and supply continuity expectations reinforce the importance of long-term lifecycle planning.

Whether these reforms ultimately translate into a substantial increase in pediatric innovation remains to be seen. However, they clearly demonstrate that pediatric medicines have become a strategic policy priority within China’s healthcare and pharmaceutical development agenda.

Companies active in the pediatric space should therefore reassess development, regulatory, market access, manufacturing, and portfolio strategies against the new framework. Early assessment will help identify where new incentives, obligations, and evidence pathways may affect future development and commercialization plans.

For additional guidance on China pediatric medicine regulation, NMPA compliance strategy, and broader Asian regulatory developments, contact Cisema today.

Further Information

• Explore Cisema’s Pharmaceutical Consulting services.

References

• Implementation Opinions on Reforming and Improving the Supply Guarantee Mechanism for Children’s Medicines  ‍
• Policy Interpretation of the ‘Implementation Opinions on Reforming and Improving the Supply Guarantee Mechanism for Children’s Medicines’  ‍
• Infographic: Understanding the ‘Implementation Opinions on Reforming and Improving the Supply Guarantee Mechanism for Children’s Medicines’